The existence of two molecular forms of D2 dopamine receptors suggests that differences in the distribution or regulation of the two forms could be exploited for the pharmacological treatment of disease. Using probes selective for each alternatively spliced variant of D2 receptor mRNA, we determined that both variants were widely distributed in rat brain and pituitary but that the ratio of the forms varied among regions. mRNA for the 444-amino acid-long variant, D24M, was the most abundant form in pituitary and neostriatum. Intermediate levels of both D24m4 mRNA and the short form, D2415, were detected in midbrain, and low levels of D2444 and D2415 mRNAs were detected in all other regions examined, including hippocampus, cerebellum, and cortex. The D2444/D2415 ratio was generally lower in the regions of low expression than in pituitary and neostriatum. Dopamine-depleting lesions increased the density of D2 receptors in the denervated neostriatum by 29% without altering the affinity of the receptors for
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[3H]spiperone. The proliferation of receptors appeared to be due to a lesion-induced increase ofup to 120% in the abundance of both variants of mRNA in the neostriatum.
When excitable tissue is denervated the tissue typically becomes supersensitive to the effects of neurotransmitters and drugs. Denervation supersensitivity has been proposed as a compensatory mechanism involved in recovery of function after nervous system damage (1) and as a mechanism of tolerance and withdrawal phenomena associated with chronic drug use (2) . Damage to the rat dopaminergic mesotelencephalic projection results in heightened sensitivity of neostriatal neurons to dopamine agonists. One manifestation of denervation supersensitivity after unilateral damage to the dopaminergic system is rotation away from the damaged hemisphere in response to systemic administration of the dopamine agonist apomorphine (3, 4) . Denervation-induced proliferation of D2 dopamine receptors is one potential cellular mechanism for behavioral supersensitivity to dopamine agonists (4) (5) (6) (7) (8) (9) .
The dopamine-depleted rat has been used as a model for parkinsonism, a disease in which degeneration of dopaminecontaining neurons leads to a reduction in the dopaminergic innervation of the basal forebrain (10, 11) . Since the conrentration ofdopamine may be decreased by 70% before patients exhibit clinical symptoms, and patients with parkinsonism appear to be supersensitive to the dopamine precursor L-dopa, it has been proposed that the development of denervation supersensitivity compensates for the loss of dopamine (12, 13 ). An increased density of D2 receptors may be one factor contributing to denervation supersensitivity in parkinsonism (14) .
Two variants of D2 receptor mRNA that result from alternative splicing of a single gene product have been identified (15) (16) (17) . The variants differ due to a stretch of 87 bases present in the third cytoplasmic loop of the long form (D2444) but lacking from the short form (D2415) described by Bunzow et al. (18) . Studies of the distribution of D2 receptor mRNA have yielded contradictory results concerning the existence and distribution of D2415 and D24" in rat brain (15) (16) (17) (19) (20) (21) (22) . We now describe the use of polymerase chain reaction (PCR) analysis, RNA slot blots, and in situ hybridization to define the distribution of each of the alternatively spliced variants in rat brain. Also, we report that denervation of D2 receptors increases the abundance of both forms of mRNA in rat neostriatum.
METHODS
Reverse Transcription (RT)-PCR. Single-stranded cDNA was produced from purified RNA by a primer extension/ reverse transcriptase reaction. RNA (2 ,ug) was dissolved in 28.5 ,l of RNase-free H20. After addition of 6.0 ,l of 0.1 M MeHgOH, the RNA was incubated at room temperature for 7 min, and then 5 min after addition of 3.1 ,ul of 0.7 M 2-mercaptoethanol. For the RT reaction, the following components were then added: 10 ,ul of 5x RT buffer, 1.25 ,l of RNasin (50 units, Promega), 1 ,ul of PCR primer (1 ,ug), 1 ,l of 25 mM dNTPs, and 2.65 ,l of avian myeloblastosis virus reverse transcriptase (50 units, Life Sciences, St. Petersburg, FL). MeHgOH, 2-mercaptoethanol, 5x RT buffer, and 25 mM dNTPs were all from the Invitrogen red module for cDNA synthesis. The primer was a 36-mer oligonucleotide (5 '-CCAGCAGATGATGAACACACCGAGAACAATG-GCAAT-3') complementary to a region of the D2 receptor cDNA extending from the 5' end of the sequence encoding membrane-spanning domain VI to nucleotide 1074 of D2415 (18) . The cDNA synthesis was carried out for 2 hr at 42°C, then inactivated at 65-70°C for 10 min. The cDNA was stored at -20°C until use. The PCR was carried out in a volume of 100 ,l including 2 p1 of the cDNA reaction mixture, 69 pl of H20, 1 ,l of forward primer and of reverse primer ("1 ,ug each), 10 and kidney. RT-PCR was performed on 2 jg of each RNA preparation and the products of the reaction were electrophoresed in an agarose gel (data not shown). A 460-base-pair (bp) band was seen in all tissues examined, but an additional, and usually more prominent, band of :550 bp was observed in all tissues except GH4ZR7 cells, which were transfected with a D2415 cDNA (27) . The 550-bp band was cloned into phage M13 and sequenced, and it is identical to D2^4 cDNA (15) . D2i hybridized only to the upper band (D2"4), whereas D2j hybridized only to D2415 (data not shown). Slot blot analysis was carried out to quantify the relative levels of the alternatively spliced forms of D2 receptor mRNA in rat tissues and brain regions. Highest levels of D2 receptor mRNA were found in striatum, with high expression also observed in pituitary (Table 1) . Mode-rate levels of D2 receptor message were found in the midbrain, and low levels in a number of other tissues, including cerebellum and hippocampus. There was no detectable hybridization of either probe to rRNA (data not shown). Distribution of the alternatively spliced variants was heterogeneous, in that D2 receptor mRNA in pituitary consisted almost exclusively of D24" (D2"4/D2415 ratio = 6.0), whereas the level of D24" was approximately twice the level of D2415 in rat striatum (D24"/D2415 = 2.4). In several other areas the two transcripts were expressed in roughly equal proportions. Results for relative levels of D2415 and D24" mRNAs obtained by in situ hybridization histochemistry were similar to those determined by slot blot analysis ( Table 2 ). The greatest discrepancy between the two techniques was observed for values in the cerebellum, which could be due to the regional heterogeneity of D2 receptor distribution within the cerebellum (28) .
Denervation-Induced Proliferation of D2 Receptors. The effect of denervation on the density of D2 receptors and levels of D2 receptor mRNA was determined 3 weeks after unilateral injection of 6-hydroxydopamine into the ventral tegmental area. The density'of D2 receptors, determined by saturation analysis of the binding of [3H]spiperone, was 400 ± 26 fmol/mg of protein in the intact neostriatum. In the denervated neostriatum, the density of D2 receptors was 509 ± 23 fmol/mg of prQtein, representing a mean increase of 29% over the number of receptors in the intact neostriatum (P < 0.05; Fig. 1 (31) . Treatment with haloperidol increases the density of D2 receptors in rat neostriatum (32, 33) but may (34) or may not (35) increase neostriatal total D2 receptor mRNA levels. As described here, destruction of the ascending dopaminergic system resulted in an increased density of neostriatal D2 receptors, although the affinity of the receptors for radioligand was not significantly changed. The lesioninduced proliferation of receptors was associated with an increased abundance of mRNA for both D2415 and D24".
These findings confirm and extend previous work (36) (1991) demonstrated by the heterogeneous distribution of the two variants, but the alternative splicing within the striatum is not regulated by the extent of innervation of the receptors by dopamine-containing terminals.
